On January 5, 2015, the Company entered into an additional license agreement with Phoenix Bio Pharmaceuticals Corporation to expand the territories covered under its original license agreement dated March 14, 2014. Under the terms of the additional license agreement, the Company acquired the marketing rights to distribute products developed by Phoenix Bio Pharmaceuticals Corporation in Australia and New Zealand for ten years. In exchange for the license, the Company has issued 250,000,000 restricted common shares at $0.016 per common share, for an aggregate value of $4,000,000.
This also explains the low float here with a 360M OS as of March 9, 2015, 250M as shown here is restricted. (From the 10Q/A The number of outstanding shares of the registrant's common stock on March 9, 2015: 361,322,812)
MediJane Holdings Inc ("MJMD") is in the business of distributing transdermal patches, capsules, sublingual sprays and other medical delivery systems for the medical marijuana industry. With sales offices opening in California and Colorado, and then expanding into a national footprint, MediJane products are designed to give Doctors the ability to give patients accurate and effective doses of cannabinoids to manage and treat specific illnesses.
As more and more is discovered about the uses of cannabis in modern medicine, a massive growth is being seen in this relatively new industry. Recently studies have been published siting treatment and/or management for fibromyalgia, migraine, PTSD, chronic pain and inflammation, autism, ADD/ADHD, crones disease, arthritis, seizures, epilepsy, skin cancer and various cancers.
MediJane is positioned between the medical practitioners and the dispensary operators, our team of pharmaceutical and medical sales representatives provide the product and knowledge bridge between these two industry advocates of medical marijuana. Giving medical practitioners smokeless alternatives that not only are made from organically produced targeted strains of cannabis, but are able to allow the patient the ability to use the product safely and accurately.
Many MediJane products are made without activating the psychotropic effects normally suffered or enjoyed by medical marijuana patients. The choice of products allows the patient to manage their condition, all without the traditional ?high?, or where needed or desired, the activated product can provide the patient with a relaxation or sedative effect.
$MJMD STOCK - WHY ALL THE $$$ FLOW, ALL OF A SUDDEN???
..... This is the question on everyone's mind after this stock hit their volume/price scanners on Friday, and of course, the IHUB breakout board. Are Cannabis stocks finally heating up? Most know that a year ago a company like MJMD would have seen its stock move from .001s to $0.40 + with this share structure and business. This year, so far, things are a bit more down to earth. Here are some points to consider, as possible reasons behind the move:
1. The move on 3/27 was NOT a paid pump and dump promotion... ref. www.pumpsanddumps.com . Because of this, the move and record volume for the stock are hinting at something much bigger.
2. speculation about MJMD's relationship with CannaVest Corp (OTC: CANV), MJMD's raw materials supplier, for a possible merger or buyout...
3. expanded relationship, or combination/merger with strategic partner Phoenix BioPharmaceuticals:
On January 5, 2015, the Company entered into an additional license agreement with Phoenix Bio Pharmaceuticals Corporation to expand the territories covered under its original license agreement dated March 14, 2014. Under the terms of the additional license agreement, the Company acquired the marketing rights to distribute products developed by Phoenix Bio Pharmaceuticals Corporation in Australia and New Zealand for ten years. In exchange for the license, the Company has issued 250,000,000 restricted common shares at $0.016 per common share, for an aggregate value of $4,000,000.
This also explains the low float here with a 360M OS as of March 9, 2015, 250M as shown here is restricted. (From the 10Q/A The number of outstanding shares of the registrant's common stock on March 9, 2015: 361,322,812)
4. Possibility that a huge purchase order will be announced for MJMD's medical marijuana products:
"To date, 23 states, along with the District of Columbia, have legalized medical marijuana and 12 others have legalized the limited use of low-THC marijuana for medical purposes."
5. Knowledge of how BIG their new product(s) may become:
New Product Development Agreement : On October 23, 2014, the Company entered into a New Product Development Agreement (the “NPD Agreement”) with Phoenix Pharms for use of Phoenix Pharms’ expertise in identifying new product business development opportunities related to expanding the Company’s product offerings. The NPD Agreement is for a period of four months at $16,000 per month. As of November 30, 2014, the Company had paid $64,000 towards the NPD Agreement and has no further obligations under the NPD Agreement.
6. Sales only just began in October 2014. Perhaps numbers now are looking very good as they expand their retail presence:
Longmont, CO / ACCESSWIRE / September 16, 2014 / MediJane Holdings Inc. (MJMD) ("MediJane") a medical cannabis company focused on the wholesale sales and distribution of smokeless medical cannabis products, is pleased to announce MediStrips are now available for sale at in dispensaries' around Sacramento, CA.
7. Based on the 360M OS and 250M restricted, the max float at 110M shares, clean balance sheet, solid asset base, first full quarter of revenues has not even been reported yet, products fully developed and expanding, this Cannabis gem is hitting everyone's radars and investors know the potential here..... $$$$$$$$$$ MJMD
Longmont, CO / ACCESSWIRE / September 12, 2014 / MediJane Holdings Inc. (OTCQB: MJMD) ("MediJane" or the "Company") to form Medical Advisory Committee.
MediJane is pleased to announce that it will be establishing a Medical Advisory Committee ("MAC"). MediJane Holdings and its technology licensor, Phoenix Bio Pharmaceuticals, have announced the planned development of an expanded panel of multidisciplinary physicians and health care professionals.
The newly-formed Medical Advisory Committee will serve the Company, providing their professional expertise in development of legalized medical cannabis (CBD, THC and CBG) products targeting specific health related conditions. The Medical Advisory Committee will include up to seven (7) members from the medical and scientific community with an expanded focus on legal medical cannabis care for conditions affecting pediatric neurology, oncology, and pain management.
"Creating a Medical Advisory Committee will enhance our established formulation and organic chemistry efforts and will provide us access to a broader scientific perspective with expanded medical experience. The MAC will also offer a wider spectrum of technical knowledge surrounding the development and acquisition of products supporting heath and wellness utilizing legalized cannabis. We are excited to form this committee and to utilize their expertise in expanding our custom formulations for cannabinoid treatments," stated Lewis "Spike" Humer, Chairman of MediJane.
MediJane is currently reviewing potential candidates for positions within the Medical Advisory Committee. We encourage additional qualified health care professionals seeking to provide their patients with alternative options for therapy to contact medico@mjmd.net for additional information.
Humer concluded, "Each day we hear of new case studies regarding the positive effects and potential impacts of medical cannabis and cannabinoid based treatments Search engines are increasingly populated with stories of the impact and promise of cannabinoid care. Personal stories of children being given new hope and increasing relief from juvenile seizures, examples of cancer patients seeing remarkable improvement in their condition or symptoms, emerging studies in the treatment of Parkinson's Disease and more appear in the continually in news. These breakthrough cases remind of our values-driven obligation to continue our mission.
The hundreds of thousands of registered patients remind us of the large-scale potential benefits of medical cannabis. The tens of thousands of people enrolling around the country to be part of medical marijuana state-registered programs supports our understanding of the increasing demand for access to cannabinoid care. We believe in the opportunity. We are committed to our mission to continue to develop and help make available new applications, products, and delivery systems for those seeking or needing them. This is why we started this journey. This is the reason we continually seek a path of progress in supporting health-enhancement, increased wellness, and helping people enhance their quality of life where we can."
LONGMONT, CO--(Marketwired - Jun 27, 2014) - MediJane Holdings Inc. (OTCQB: MJMD) ("MediJane" or "MJMD" or the "Company") is pleased to announce that further to its press release dated May 27, 2014, the Company's new product "MediStrip Relaxation" dissolvable oral strips are now available for sale at www.GoKush.com.
GoKush.com (www.GoKush.com) is part of a members only collective comprised of verified legal medical marijuana patients in the State of California. The GoKush platform allows same day and overnight delivery of medical marijuana to its registered customer base.
MediJane's MediStrip Relaxation will be offered to GoKush customers at an introductory price of $12.50 for a single cool-mint strip or $87.50 for a package of 7. Each MediStrip Relaxation is individually packaged for freshness and consistency, and contains 25 mg THC, 2 mg CBD, and 2 mg CBN derived from high-quality Cold Ethanol extracted cannabis oil.
"We are excited to finally be ready to offer GoKush patients this exciting, unique, and convenient new product from MediJane," stated GoKush founder Mac Bagley. "We are very pleased that MediJane has been able to devise and formulate such innovative delivery systems for the medical marijuana space, so I encourage our existing and potential new customers to visit www.GoKush.com to try this new product at an introductory price before it's gone."
Lewis "Spike" Humer, Chairman of MediJane Holdings, concluded, "This delivery further solidifies our relationship with GoKush and opens the door for potential new MediJane products to be provided through GoKush. This also represents a continuation of our overall growth as a company and demonstrations our commitment to becoming and remaining the premier medical cannabis company in the market."
For additional information regarding MediStrip Relaxation, visit www.mjmd.net/medistrip-relaxation/
LONGMONT, CO--(Marketwired - May 27, 2014) - MediJane Holdings Inc. (OTCQB: MJMD) ("MediJane" or "MJMD" or the "Company") is pleased to announce that it has received its first wholesale purchase order for the recently launched "MediStrips - Relaxation" dissolvable oral strips. The order is for an initial 15,000 units to be purchased by GoKush.com as part of an ongoing product offering.
GoKush.com is expected to begin promoting MediStrips through its online patient portal over the coming weeks. The products will be available for an introductory price of $12.50. Each MediStrip is individually packaged for freshness and consistency. New and existing GoKush members will be able to order online and have MediStrip Relaxation shipped directly to their home.
"We are very excited to be providing our licensed cannabis patients with such a unique smokeless product," stated GoKush founder Mac Bagley. "The MediStrip Relaxation dissolvable oral strip is truly a product that's ahead of the industry curve. We're looking forward to introducing MediStrip Relaxation to our valued clients across California and to expand our MediJane product offerings in the near future."
GoKush.com (www.GoKush.com) is part of a member only collective comprised of valid and legal medical marijuana patients. All GoKush customers are verified with their recommending physician to ensure only licensed patients can access their range of products. The GoKush.com delivery service enables registered medical marijuana patients? to safely and legally access their cannabis-based care products within the convenience of their own home.
"MediJane's MediStrip Relaxation oral strips provide a convenient smokeless alternative for licensed medical cannabis patients," commented Spike Humer, Chairman of MediJane Holdings. "With a minty-fresh flavor and fast acting results, a MediStrip Relaxation patient can achieve a state of relaxation or pain management in a discrete format of a thin breath strip."
"We are proud to expand our medical cannabis product offerings as we continue the implementation of our corporate growth strategy. With each new MediJane product, such as the MediStrip, we provide licensed patients with high quality, smokeless, and adult oriented medical cannabis products, and give doctors the proper tools they need to accurately and safely recommend and manage their patients' medical cannabis treatment program which advances our chief aim and core objectives," concluded Humer.
MJMD Finalizes New Medical Cannabis Medi-Strips Product Line
LONGMONT, CO--(Marketwired - May 23, 2014) - MediJane Holdings Inc. (OTCQB: MJMD) ("MediJane" or "MJMD" or the "Company") is pleased to announce that it has approved the final formulation as well as product branding for its new line of dissolvable oral medical cannabis "Medi-Strips."
Fast dissolving films are gaining interest as an oral delivery alternative to tablets and pills. The mint flavored Medi-Strips films are designed to dissolve upon contact with a wet surface, such as the tongue, allowing the patient to take the product without need for additional liquid. As the drug is directly absorbed into systemic circulation, degradation in gastrointestinal tract and first pass effect can be avoided. This convenience factor provides both a marketing advantage and increased patient compliance. Over-the-counter films for pain management and motion sickness have already been successfully commercialized in the US markets and mainstream consumer acceptance increases daily. Combining medical cannabis with this delivery system gives the user a discreet, controlled dose of nighttime pain relief without any oral ingestion complications that can often afflict terminal patients.
"We are absolutely elated to be providing such an innovative and cutting edge delivery system for cannabinoids. Our thin film medicated strips are an orally absorbed, fast acting, dissolvable medical cannabis delivery platform that will provide patients quick and long lasting pain relief. I am also excited about the extensions into tertiary demographics, such as geriatrics where oral ingestion and choking hazards are common place. I believe this product will have mainstream, as well as, targeted appeal throughout the medical cannabis marketplace," commented Dr. Joseph Cohen, Chief Medical Officer of MediJane Holdings.
Spike Humer, Chairman of MediJane, concluded, "With all development aspects of this new product line complete, we are very eager to get MediJane Medi-Strips into customer hands quickly wherever legal medical cannabis is sold. This product launch solidifies the direction we are headed in as a company which is to provide medical cannabis to patients utilizing the most innovative, accurate, and reliable delivery systems available."
LONGMONT, CO--(Marketwired - May 16, 2014) - MediJane Holdings Inc. (OTCQB: MJMD) ("MediJane" or "MJMD" or the "Company") today reported that further to its recently launched California expansion plan, the Company is pleased to announce that it has successfully concluded a recruitment process and has appointed Franceen Reeves as MediJane's new Head of Sales for the state of California.
Ms. Reeves graduated from Texas Christian University with a Bachelor of Science in Nursing (BSN). Upon graduation, she was commissioned into the United States Air Force as a 2nd Lieutenant and began working as a Security Forces Officer. As acting Officer In-Charge of Training & Resources for the 72nd Security Forces Squadron, she was responsible for a team of 36 personnel, assets worth over $15.5M (including 25 vehicles, 1054 weapons in the armory, and managed a budget of $1.8M. Ms. Reeves was the lead training coordinator for over 430 base-wide representatives on anti-terrorism training measures post 9-11. She was also influential in attaining $3.4M anti-terrorism funding from higher headquarters for the mitigation of Tinker Air Force Base's internal and external vulnerabilities.
Ms. Reeves decided to pursue her passion and cross-train into healthcare for her last two years of military service. She was moved to Andrews Air Force Base for her remaining time in the force. Ms. Reeves acted as In-House Supervisor for the Multi-Specialty Unit at Malcolm Grow Hospital and was then promoted to the rank of Captain.
Following her service in the U.S. military, Ms. Reeves worked at Kindred Healthcare for a few years. Although she enjoyed the training she received from a medical and clinical standpoint, she wanted to move toward the business side of healthcare and decided to pursue the medical device industry.
After Kindred Healthcare, she went to work for Boston Scientific as a Clinical Specialist in the Neuromodulation Division. Her role at Boston Scientific was educating anesthesiologists and orthopedic surgeons on the use of an implantable pain-relief device. She programmed the device intra and post operatively, running over 45 cases in the OR. She also managed the largest account in the territory, which generated $1M in revenue a year.
She has spent the last 5 years within the Medical Device Industry, which included her most recent clinical sales position working as a contractor for Gambro. In this position, she worked with cardiologists, nurse managers, medical directors, and CNO's. Gambro AB, a global leader in the development, manufacturing, and supply of products and therapies for kidney and liver dialysis, myeloma kidney therapy, and other extracorporeal therapies for chronic and acute patients, was acquired by Baxter International Inc. in 2012.
"Ms. Reeves' vast clinical and practical medical experience, personnel & resource management, and hands-on sales skills makes her an ideal candidate for the position of MediJane Head of Sales for California," commented Ronald Lusk, CEO of MediJane Holdings Inc. "Her being a proud patriot and military veteran also assisted me in the decision to add Franceen to the MediJane team."
LONGMONT, CO--(Marketwired - May 14, 2014) - MediJane Holdings Inc. (OTCQB: MJMD) ("MediJane" or "MJMD" or the "Company") Further to the Company's recently announced California expansion plan, MediJane Holdings is pleased to announce that it has completed a distribution agreement with GoKush.com
GoKush (www.gokush.com) is part of a not-for-profit California Cooperative Corporation that is dedicated to providing safe and legal access to medical marijuana for patients throughout California. A medical marijuana fulfillment and delivery service, GoKush.com provides private, professional, knowledgeable, and compassionate access medical marijuana to its customers. GoKush is a members only collective comprised solely of members who are valid, legal medical marijuana patients.
The GoKush.com delivery platform allows registered medical marijuana patients to receive their cannabis-based care and products within the safety and convenience of their own home.
Importantly for patients in California seeking to use MediJane's high quality medically oriented products, including CannaMist, the Daytime plus CBD capsules and future products, home delivery provides a secure and discrete way to fulfill their recommendation and ensure consistency of delivery and accessibility.
"As MediJane Holdings continues implementing its California growth strategy, scalable infrastructure and effective implementation is vital. We believe GoKush.com is a highly reliable fulfillment platform for retail medical dispensaries to ensure consistency, availability, and legal access to the Company's products. Through GoKush.com we can provide both customer direct and dispensary fulfillment services," stated Ron Lusk, CEO of Medi-Jane.
"Our alignment with GoKush.com allows us to expand our commitment to serving our shareholders, stakeholders, partners, and clients in the emerging market of legalized medical cannabis," added Spike Humer, MediJane Chairman.
In addition, the GoKush.com platform will enhance logistical support to legal medical marijuana dispensaries in placing their refill orders of MediJane products. "We believe it's vital to the growth of our mission to provide the highest quality, consistency of availability, and convenient access to our products," concluded Humer.
GoKush.com has same day and overnight delivery option within California. Visit www.gokush.com to register, if you have a medical cannabis license (verification required).
LONGMONT, CO--(Marketwired - May 12, 2014) - MediJane Holdings Inc. (OTCQB: MJMD) ("MediJane" or "MJMD" or the "Company") is pleased to announce that the Company has appointed Mr. Russell G. Stone as its new Chief Operating Officer (COO).
Since 2002, Mr. Stone has been a managing member and active principal of Stone Financial Group, LLC, Jo-Bar Enterprises, LLC, and Stone Brothers Capital LLC -- the business of which were created to participate in a diversified array of investment offerings that include, but are not limited to, lending, hospitality, real estate, medical, technology, and the secondary life insurance market. Mr. Stone's responsibilities within the companies include investor and broker relations, portfolio analysis, and management. Additionally, Mr. Stone is responsible for the monitoring of loans and the seeking of new investment opportunities for the family of companies.
Mr. Stone also co-founded Finiti Branding Group, LLC ("FBG") in 2011. FBG was a privately held company established to take advantage of the rapidly growing electronic cigarette industry. FIN electronic cigarettes (www.fincigs.com) can now be found in national chains such as Walgreens, AM-PM, and Walmart to name a few. FBG was acquired in 2014. Mr. Stone had many responsibilities within FBG including President, VP of Supply Chain, and VP of Business Insight. Within his role as FBG President, Mr. Stone was responsible for all aspects of FBG's business including the organizational structure, evaluating staffing needs, and driving the vision of the company. Mr. Stone was the general liaison to the various FBG department heads to ensure proper communication and coordination of information.
Throughout his career, Mr. Stone has had an entrepreneurial spirit that has led him to assist and build several startup companies. He began his career within the culinary fields in which he was involved in two restaurant openings where he held numerous positions. He currently is a founding member of a startup beverage business where he acts as a consultant and advisor to the company on its distribution, sales and merchandising, and roll out strategies.
Mr. Stone graduated from the University of Kansas in 1996 with a Bachelor of Science degree in Business Administration with a concentration in Communication Studies. In addition, he holds an associate degree from the culinary program at Kendall College in Evanston, IL.
Lewis "Spike" Humer, Chairman of MediJane Holdings Inc., commented, "As a company that is growing in a new and quickly evolving industry, it's integral that all cogs in the wheel are operationally effective. With the addition of Russell Stone as our new Chief Operating Officer, our team now has more back end knowledge and experience ranging from rapid supply chain management to complex inventory controls. Compounding his operations credentials is his vast front end experience having started and sold several successful businesses. These factors, combined with his financial services experience, make Russell Stone an ideal fit for MediJane's business strategy and the ongoing intricacies of being a publicly traded company."
LONGMONT, CO--(Marketwired - May 6, 2014) - MediJane Holdings Inc. (OTCQB: MJMD) ("MediJane" or "MJMD" or the "Company") is pleased to announce that the "Canna-mist" sublingual cannabinoid spray, a product whose intellectual property was recently acquired by Phoenix Bio Pharm ("PBP"), will now be branded and sold under the MediJane name. The exclusive Canna-mist licensing and distribution agreement is another step forward for MediJane in expanding the suite of medical delivery systems available as the Company continues to expand and establishes itself as a leading medical cannabis company and as a brand.
Canna-mist is the brainchild of renowned botanist Pamela Clum, who recently joined the MediaJane Advisory Board. The sublingual spray delivery system allows for fast absorption of active cannabinoid alkaloids through the mucous system of the mouth and directly into the bloodstream for fast, effective, and smokeless symptom relief for the patient.
"The sublingual delivery system is one of the most effective and convenient drug delivery systems available for patients requiring regular self-medicated doses and, in the case of Canna-mist, provides the patient with fast relief from pain and inflammation," commented Lewis "Spike" Humer, Chairman of MediJane Holdings Inc. "Our sales, marketing, and manufacturing team is currently finalizing the product and we expect to have the newly branded MediJane "Canna-mist" ready for distribution in targeted states across the country in just a few weeks."
LONGMONT, CO--(Marketwired - May 2, 2014) - MediJane Holdings Inc. (OTCQB: MJMD) ("MediJane" or "MJMD" or the "Company") is pleased to announce that Pamela Clum has joined the newly formed Advisory Board of the Company.
Since 2002, Pamela Clum has been the chief product formulator, developer, and marketer of the unique "Canna-mist" brand of sublingual cannabinoid (CBD) spray which is now part of MediJane's portfolio of products exclusively licensed from Phoenix Bio Pharmaceuticals Corporation. Ms. Clum is the co-author of "Ecophysiology of Short Rotation Forest Crops" and has presented botany focused research abstracts at several scientific conferences. Pamela holds a Master of Science degree in Botany from the University of Washington.
"Pamela's addition to the MediJane Advisory Board will provide our company with access to remarkable insights from an industry pioneer in the medical cannabis sector," commented Ronald Lusk, CEO of MediJane Holdings Inc. "Her extensive experience and understanding of formulating and developing innovative delivery systems, and her particular familiarity with our Canna-mist product make her an invaluable source of industry knowledge going-forward."
Pamela Clum concluded, "I'm very excited to join the MediJane Advisory Board. I'm looking forward to contributing my experience to support an emerging, expanding, and fast-moving industry. I hope to assist MediJane in many aspects of business development such as formulations, outsourcing, branding, manufacturing, and anywhere else we feel my skills can have a positive impact."
LONGMONT, CO--(Marketwired - Apr 29, 2014) - MediJane Holdings Inc. (OTCQB: MJMD) ("MediJane" or "MJMD" or the "Company") is pleased to announce that the Company has begun its planned California expansion strategy.
Since Assembly Bill 2312 was passed in 2012, the medical marijuana industry has thrived in the State of California. With only medical marijuana currently legal, the California market is ripe for MediJane to launch its first product in the state. To realize this goal, regulatory applications and filings are in place and steps are being taken to ensure that MediJane products will be compliant with all California laws.
"State by state product regulatory compliance is going to be an on-going factor for any growing medical marijuana focused company," commented Ronald Lusk, CEO of MediJane Holdings Inc. "Another major factor to our long-term success will be our ability to build and maintain a motivated, capable, and experienced sales force across the country."
Mr. Lusk concluded, "Now that we have our State of California regulatory applications and filings in place, we have started the search for our new California sales manager. Because MediJane is a medical marijuana company with innovative proprietary medical delivery systems, the California sales manager position will require a delicate balance of science and sales, and will also need to have a diverse understanding of the medical and recommending doctors industries. We are confident that our current efforts to fill this important position will be successful and that MediJane products will be well received in California."
The Company anticipates that the innovative MediJane "Daytime plus CBD" pain and inflammation management product could be on store shelves in California within the next 60 days, subject to final regulatory approvals. "Daytime plus CBD" targets chronic, neuropathic, arthritic, and back pain, without drowsiness. The four (4) hour dosage allows for accurate and controlled delivery of cannabinoids directly into the pain sufferer's system. This smokeless alternative is MediJane's initial launch into the chronic pain management market, which is estimated at over $45 billion annually in North America.
LONGMONT, CO--(Marketwired - Apr 25, 2014) - MediJane Holdings Inc. (OTCQB: MJMD) ("MediJane" or "MJMD" or the "Company") is pleased to announce that Lewis "Spike" Humer has been named as Chairman and Director of Company. Mr. Humer is also currently CEO of Phoenix Bio Pharmaceuticals Corporation ("Phoenix Bio Pharm"), the Colorado-based developer of certain medicinal cannabis products and delivery systems exclusively licensed to MediJane Holdings in North America.
"I'm very excited to be able to provide additional corporate guidance and oversight to MediJane as it continues to grow and expand as a company and as a brand," commented Lewis "Spike" Humer, Chairman of MediJane Holdings Inc. "Phoenix Bio Pharm and MediJane Holdings share many of the same corporate goals and challenges, so our success can be built together with a growing strategic relationship. I look forward to helping expand MediJane to its full potential as a strong, trusted, and profitable leader in the medical cannabis industry."
Lewis "Spike" Humer is a seasoned business executive with more than twenty years of field proven, sales oriented, and results driven experience. After working with the Susquehanna Pfaltzagraff Company, a company engaged in the manufacturing, distribution, retail sales media, real estate, and more, from 1976 to 1996 in a variety of leadership, managerial, and executive positions, Mr. Humer served as a corporate CEO, COO, Chairman and VP of Sales and VP of Marketing in both public and private enterprises. He has extensive experience as a keynote speaker, professional trainer, organizational consultant, seminar leader, and program facilitator.
From 2001 to 2003, Mr. Humer served as President and CEO of ITEX Corporation, a company engaged in franchise management and administration of an international barter exchange. Mr. Humer designed and implemented a corporate turnaround and organizational restructuring. Prior to joining ITEX Corporation, Mr. Humer served as an executive and consultant to various small-to-midsize enterprises throughout the United States. In addition, Mr. Humer has participated in various other business initiatives including corporate re-engineering, company start-ups, mergers and acquisitions, and raising capital for investment in various business enterprises.
Mr. Humer has been quoted or appeared in a wide of publications such as Equities Magazine, BarterNews, as well as several Business Journals and newspapers throughout the world. Mr. Humer has been featured on such programs as The American Scene Business Radio, World Business Review, Stu Taylor Business Radio, and countless other business broadcasts. In addition, Mr. Humer served as board member for several organizations and corporations, including the Global Board of Directors of the International Reciprocal Trade Association.
LONGMONT, CO--(Marketwired - Apr 16, 2014) - MediJane Holdings Inc. (OTCQB: MJMD) ("MediJane" or "MJMD" or the "Company") is pleased to announce that Dr. Joseph Cohen has agreed to assume the role of Chief Medical Officer and join the board of directors of the Company.
Dr. Cohen has developed a complimentary and innovative approach to wellness that combines functional medicine with the utilization of natural substances, such as medicinal cannabis and other formulations. Holos Health, a Dr. Cohen supported Medical Marijuana Evaluation facility in Boulder, Colorado, was the recipient of the Best of Boulder Award in 2012 and 2013 for Best Medical Marijuana Evaluations and Best Alternative Health Care Practitioners. Dr. Cohen also holds the position of Chief Medical Advisor to a significant Connecticut licensed medical marijuana company.
"I'm absolutely thrilled to be involved in a project that I'm so passionate about," stated Dr. Cohen. "This industry is on the cusp of fantastic new medical breakthroughs and I'm proud to be working with MediJane to do our part to ensure the long-term sustainability of medical delivery systems for the safe and legal access to medical marijuana."
Having moved to Boulder, Colorado, in 1991, Dr. Cohen practiced obstetrics and gynecology initially with the Boulder Women's Clinic and then formed Full Circle Health Associates, a multi-discipline group that combined conventional and integrative medicine. During that time, Dr. Cohen was both the medical director of the Center for Integrative Therapeutics at Longmont United Hospital, as well as department chair in OB/GYN and pediatrics. Under his direction, integrative approaches such as acupuncture, reiki, and massage therapy were brought into a hospital setting. In 1993, Dr. Cohen was awarded "Best Delivery Man" by Denver Westward magazine. During his 30 years' experience as an obstetrician/gynecologist, he assisted women in approximately 10,000 births.
In 2001, Dr. Cohen left Colorado and began working with women from several different cultures. This included Hispanic women at The Medical Center of Aurora where he worked as a hospitalist, Native American women in Wyoming (Arapaho and Shoshoni tribes) and Maori women in Whanganui, New Zealand. During the past decade he has been studying functional medicine. Since returning to Boulder from New Zealand in 2009, he has integrated medical marijuana into his holistic functional medicine practice.
In addition to carrying a private medical practice in Boulder, Colorado, Dr. Cohen is currently medical director for the Natural Plant Initiative for Cancer Research, Holos Health, and for Journey 2 Life, an alternative and holistic health services provider, and is also a member of the Institute for Functional Medicine. Dr. Cohen received his Doctor of Osteopathy degree in 1979 after completing his residency in obstetrics and gynecology at Bridgeport Hospital in affiliation with Yale University School of Medicine.
LONGMONT, CO--(Marketwired - Apr 10, 2014) - MediJane Holdings Inc. (OTCQB: MJMD) ("MediJane" or "MJMD" or the "Company") is pleased to announce that it has retained the services of patent and intellectual property law firm Peacock Meyers, P.C. ("Peacock Meyers") to file all necessary and requisite documents with the United States Patent and Trademark Office (USPTO) to secure the trademark "MediJane" or any combination as it applies to the medical marijuana industry.
In addition, Peacock Meyers will also be responsible for all individual MediJane product trademarks, registrations, and possible patent filings and IP protection on current and future products.
"The protection of our intellectual property and trademarks will be very important as we expand and cultivate our brand identity and recognition as the Company grows," stated Ronald Lusk, CEO of MediJane Holdings Inc. "As a medical marijuana company and brand, it is our mission to maintain and ensure the highest levels of quality, consistency, and effectiveness of our products and delivery systems. We believe that the 'MediJane' name encompasses that brand vision by incorporating both traditional and emerging characteristics of the medical cannabis industry. Having a firm like Peacock Meyers guiding us with intellectual property issues can help to ensure the protection and longevity of our valuable brand."
Founded in 1995, Peacock Meyers, P.C. (www.peacocklaw.com) is a full-service intellectual property law firm based in New Mexico with offices in New York, Washington, D.C., and Tulsa, Oklahoma. Peacock Myers provides high quality intellectual property law services to all clients, from education and government entities to large and small businesses and individuals.
LONGMONT, CO--(Marketwired - Mar 28, 2014) - MediJane Holdings Inc. (OTCQB: MJMD) ("MediJane" or "MJMD" or the "Company") is pleased to announce that it has become a member and sponsor of the National Cannabis Industry Association (NCIA).
The NCIA is the only national trade association dedicated to advancing the interests and standardization of a safe, legal, and responsible cannabis industry. NCIA is leading the unified and coordinated campaign to ensure this emerging sector is treated fairly under federal law and to promote the growth of a responsible and legitimate cannabis industry. NCIA currently runs the only cannabis industry Political Action Committee in the country.
Mr. Ronald Lusk, CEO of MediJane Holdings Inc., commented, "The National Cannabis Industry Association was founded on the basic principle of power in numbers. Today, the growing number of American businesses involved in the state-legal cannabis industries represent what we believe to be a newly established economic force in this country. It is this ideal that attracted MediJane to join the NCIA to align ourselves with other leading and like-minded companies and professional organizations in such a rapidly developing industry."
MediJane Holdings' membership in the National Cannabis Industry Association means being represented alongside other top businesses committed to building a strong and prosperous future for cannabis-based enterprises. In addition to enhanced political representation, NCIA membership offers unparalleled networking opportunities, elevated national brand awareness and industry recognition, exclusive access to in-depth analysis of the cannabis industry and an information portal, monthly newsletter, exclusive events, and discounts.
For additional information regarding the National Cannabis Industry Association, visit www.thecannabisindustry.org.
LONGMONT, CO--(Marketwired - Mar 24, 2014) - MediJane Holdings Inc. (OTCQB: MJMD) ("MediJane" or "MJMD" or the "Company") is pleased to provide this discussion regarding its recent acquisition of the exclusive North American license to certain medicinal cannabis products and delivery systems developed by Colorado-based Phoenix Bio Pharmaceuticals Corporation ("Phoenix Bio Pharm"). In addition, this licensing agreement should allow MediJane to enhance Phoenix Bio Pharm's established relationships with physicians, scientists, product developers, biochemists, botanists, pharmacists, operators of growing facilities, dispensaries, and production facilities within the pharmaceutical and medical cannabis industries.
Mr. Ronald Lusk, CEO of MediJane, commented, "While most companies within the booming marijuana sector are focused on crop optimization and capital intensive brick and mortar operations, MediJane's mission and focus is obtaining unique, innovative, and efficient delivery of medicinal marijuana to the target treatment area of the patient. Many industry experts predict that state legislation of medical cannabis will far outpace recreational legalization, and as such, MediJane's prime directive will remain focused on building a portfolio of pharmaceutical grade medical cannabis products and delivery systems."
MediJane's initial product launch will be the release of what we believe to be an innovative "Daytime Pain plus CBD" capsule. The pain and inflammation reducing pill targets chronic, neuropathic, arthritic, and back pain, without drowsiness. The four (4) hour dosage allows for accurate and controlled delivery of cannabinoids directly into the pain sufferer's system. This smokeless alternative is MediJane's initial launch into the chronic pain management market, which is estimated at over $45 billion annually in North America.
"We expect the Daytime Pain plus CBD capsule to be just the beginning for MediJane. In addition to a wide range of condition specific capsules and transdermal patches, many other medicinal marijuana products and delivery systems, including vaporizers, topical creams, and spray mists, are also being developed under the Phoenix Bio Pharm License Agreement. Our next phase of expansion should include gaining more mainstream credibility for it products within the medicinal marijuana community as more states legalize medical cannabis. It is one of our primary goals to ensure that all products will someday be available in traditional retail outlets like pharmacies and pain management clinics across the country and internationally," stated Mr. Lusk.
Mr. Lusk continued, "Over the coming days and weeks, MediJane plans to accelerate its growth strategy. Expanding our team of expert medical and marijuana project partners who can lead the charge in executing our business plan, providing insights and contacts to help enable MediJane to launch a national model for safe and legal access to cannabinoid based medicines." Lusk continued, "The next logical step is to begin a national state by state roll out. We will identify states based on distribution infrastructure, state policies, and market potential."
Spike Humer, CEO of Phoenix Bio Pharmaceuticals, concluded, "We have built an exceptional team of professionals that has allowed us to establish a host of significant relationships within the pharmaceutical and medicinal marijuana industries. We believe that these existing relationships will help to integrate and implement many of MediJane's growth strategies and resources as they release, roll out, and create distribution nationally in the ever increasing number of states where laws allow patients safe and legal access to medical marijuana products."
------------------------------------------------------------------ MJMD Enters Medicinal Marijuana Sector With Phoenix Bio Pharm License Agreement
LONGMONT, CO--(Marketwired - Mar 21, 2014) - MediJane Holdings Inc. (OTCQB: MJMD) ("MediJane" or "MJMD" or the "Company") is pleased to announce that it has entered into a License Agreement with Phoenix Bio Pharmaceuticals Corporation ("Phoenix Bio Pharm"), a Colorado-based developer of medicinal cannabinoid products and delivery systems for the treatment and management of illnesses.
As per terms of the License Agreement, MediJane has acquired an exclusive North American license for all intellectual property, processes, and expertise related to certain medicinal cannabinoid products and delivery systems developed by Phoenix Bio Pharm and its team.
Medicinal cannabis products falling under the License Agreement include transdermal patches, orally administered extracts, concentrated extracts for vaporizers and inhalers, sublingual and buccal dispensing products and extraction technology, suppository delivery systems, salves, creams, gels, lotions, and liquid extracts, and any products or active ingredients sources through Phoenix Bio Pharm affiliates or third party suppliers or licensors. The Company will also have the right to sublicense the rights and to utilize Phoenix Bio Pharm copyrights for marketing and distribution purposes.
In consideration of the license, the Company issued 26,000,000 restricted shares of its common stock to Phoenix Bio Pharm. These shares were issued pursuant to an exemption from registration relying on the exemption from registration provided for under Rule 506 of Regulation D, promulgated under the United States Securities Act of 1933, as amended.
"We are extremely excited to have completed the acquisition of the exclusive North American rights to Phoenix Bio Pharmaceuticals' innovative medicinal marijuana products and delivery system technologies," commented Ronald Lusk, President of MediJane Holdings Inc. "The market potential for medicinal marijuana products utilizing these new technologies is absolutely enormous and I look forward to implementing our growth strategy and ramping up our marketing efforts in the very near future."
My posts are NOT a buy/sell recommendation, Do your OwnDD, before you buy any stock - I reserve the right to buy/sell any stock or any security I post about or not.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
